Table 3.
Summary Table of Objective Response According to BRCA1 mRNA Expression Level in the Two Treatment Arms or According to the Two Treatment Arms in the Two BRCA1 mRNA Expression Level Groups
| Variable | BRCA1-High Group |
BRCA1-Low Group |
Gefitinib |
Gefitinib + Olaparib |
||||
|---|---|---|---|---|---|---|---|---|
| Gefitinib + Olaparib (n = 23) | Gefitinib (n = 23) | Gefitinib + Olaparib (n = 17) | Gefitinib (n = 28) | BRCA1-High (n = 23) | BRCA1-Low (n = 28) | BRCA1-High (n = 23) | BRCA1-Low (n = 17) | |
| Objective response | ||||||||
| Complete response, N (%) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (3.57) | 0 (0.00) | 1 (3.57) | 0 (0.00) | 0 (0.00) |
| Partial response, N (%) | 17 (73.91) | 14 (60.87) | 13 (76.47) | 17 (60.71) | 14 (60.87) | 17 (60.71) | 17 (73.91) | 13 (76.47) |
| Stable disease, N (%) | 3 (13.04) | 7 (30.43) | 3 (17.65) | 8 (28.57) | 7 (30.43) | 8 (28.57) | 3 (13.04) | 3 (17.65) |
| Progressive disease, N (%) | 2 (8.70) | 2 (8.70) | 1 (5.88) | 1 (3.57) | 2 (8.70) | 1 (3.57) | 2 (8.70) | 1 (5.88) |
| Not assessable, N (%) | 1 (4.35) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (3.57) | 1 (4.35) | 0 (0.00) |
| p value test (Fisher) | 0.4012 | 0.8663 | 0.9705 | 1.0000 | ||||
| Objective response rate, N (%) | 17 (73.91) | 14 (60.87) | 13 (76.47) | 18 (64.29) | 14 (60.87) | 18 (64.29) | 17 (73.91) | 13 (76.47) |